Northbrook biotechnology company, Clarus Therapeutics, Inc. today announced the appointment of Bela S. Denes, M.D. to the newly created role of chief medical officer. Dr. Denes has over 35 years of urology experience as a laboratory researcher, clinical investigator, pharmaceutical program director and practicing physician. Dr. Denes most recently served as senior medical director at Abbott Laboratories where he led therapeutic drug discovery and development efforts in their Men’s Health Division.
Commenting on the appointment, Robert E. Dudley, Ph.D., chief executive officer of Clarus Therapeutics said, “Bela’s extensive clinical and industry experience in urology and men’s health will be invaluable as CLR-610, our oral testosterone replacement candidate, nears the end of Phase 3 clinical development.”
CLR-610 is a softgel capsule that contains a testosterone (T) prodrug, T undecanoate, that is formulated to foster absorption via the intestinal lymphatic pathway. Patient enrollment has concluded in a Phase 3 trial of CLR-610 and top-line results are expected in the third quarter of 2012.
Find out what's happening in Northbrookfor free with the latest updates from Patch.
More information on the company and Dr. Denes may be found at www.clarustherapeutics.com.
